Translational Models of Parkinson’s Disease and related Movement Disorders
- 1st Edition - November 26, 2024
- Latest edition
- Editor: Wael Mohamed
- Language: English
Translational Models of Parkinson’s Disease and Related Movement Disorders focuses on cutting-edge techniques for creating and validating current Parkinson’s Disease translati… Read more
Translational Models of Parkinson’s Disease and Related Movement Disorders focuses on cutting-edge techniques for creating and validating current Parkinson’s Disease translational experimental models. Various characteristics of these models are examined, including the prion-like properties of -synuclein, mitochondrial functions connected to the PINK1-Parkin pathway/CHCHD2, the endolysosome pathway connected to LRRK2, VPS35, and ATP13A2 using cultured cells (including patient iPS cells). This book also highlights the future possibilities of introducing new models for Parkinson’s Disease and related movements disorders, underscoring current advancements, pre-clinical and clinical developments, and future scope related to numerous models.
- Highlights induction and validation of different available experimental models of Parkinson’s Disease
- Provides a comparative prospect of different experimental models of Parkinson’s Disease
- Discusses the advantages and disadvantages of each model, including associated limitations
Student, Researchers and Clinician in Neuroscience, Neurology and Movement disorders
Section I. Understanding PD and related movement disorders
1. Neuroinflammation, glymphatic system, and Parkinson's disease
2. Pharmacotherapy of PD and related movements disorders and their limitations
3. Diagnosis and biomarkers of Parkinson's disease and related movement disorders
4. OMICS and bioinformatics in Parkinson disease and related movements disorders
5. Modeling Parkinson's disease with the alpha-synuclein protein
6. α-Synuclein seeding assay and analysis
Section II. Mammalian models of Parkinson's disease
7. SHH, nurr1, pitx3, and en1 models for Parkinson's disease
8. Stem cell for PD: Technical considerations
9. Deep brain stimulation using animal models of Parkinson's disease
10. The MitoPark mouse model of Parkinson's disease
11. The beta-sitosterol beta-D-glucoside (BSSG) rat model of Parkinson's disease
Section III. Invertebrate models of Parkinson's disease
12. SCA1 zebrafish model
13. Various zebrafish models of Parkinson's disease: What gives us hope
14. Drosophila PD model
15. Caenorhabditis elegans models of tauopathy
16. LRRK2 in Caenorhabditis elegans model
Section IV. Ethics and regulations related to translational PD models
17. Confounding factors for validation of PD models
18. Neurobehavioral characterization of PD models
19. Ethical regulations for induction and validation of PD models
20. The OMICS and PD models: Hopes or hypes
21. Parkinson's disease from an Ayurveda perspective: Opportunities and challenges for further research
1. Neuroinflammation, glymphatic system, and Parkinson's disease
2. Pharmacotherapy of PD and related movements disorders and their limitations
3. Diagnosis and biomarkers of Parkinson's disease and related movement disorders
4. OMICS and bioinformatics in Parkinson disease and related movements disorders
5. Modeling Parkinson's disease with the alpha-synuclein protein
6. α-Synuclein seeding assay and analysis
Section II. Mammalian models of Parkinson's disease
7. SHH, nurr1, pitx3, and en1 models for Parkinson's disease
8. Stem cell for PD: Technical considerations
9. Deep brain stimulation using animal models of Parkinson's disease
10. The MitoPark mouse model of Parkinson's disease
11. The beta-sitosterol beta-D-glucoside (BSSG) rat model of Parkinson's disease
Section III. Invertebrate models of Parkinson's disease
12. SCA1 zebrafish model
13. Various zebrafish models of Parkinson's disease: What gives us hope
14. Drosophila PD model
15. Caenorhabditis elegans models of tauopathy
16. LRRK2 in Caenorhabditis elegans model
Section IV. Ethics and regulations related to translational PD models
17. Confounding factors for validation of PD models
18. Neurobehavioral characterization of PD models
19. Ethical regulations for induction and validation of PD models
20. The OMICS and PD models: Hopes or hypes
21. Parkinson's disease from an Ayurveda perspective: Opportunities and challenges for further research
- Edition: 1
- Latest edition
- Published: November 26, 2024
- Language: English
WM
Wael Mohamed
Dr. Wael Mohamed Yousef Mohamed is Professor of Basic Medical Science at the International Islamic University Malaysia, with over 20 years of experience in translational brain research and longevity science. He earned his MD and MSc in Clinical Pharmacology from Meoufia Medical School, Egypt, and his PhD in Neuroscience from The Pennsylvania State University. His research focuses on aging-related neurodegeneration, particularly Alzheimer’s and Parkinson’s diseases, aiming to understand the biological mechanisms of aging and develop therapies to extend healthspan. Dr. Mohamed investigates how aging influences neurodegenerative processes and seeks targeted interventions to promote healthy longevity. He is a member of leading neuroscience societies, including the Society for Neuroscience. His prior editorial work with Elsevier includes titles on neurodegenerative and movement disorders, reflecting his expertise in aging, neurodegeneration, and longevity.
Affiliations and expertise
Neuroscientist and Pharmacologist, Kulliyyah of Medicine, International Islamic University Malaysia; Founder and Chair, AfrAbia PD Genomic ConsortiumRead Translational Models of Parkinson’s Disease and related Movement Disorders on ScienceDirect